KalVista Pharmaceuticals Inc (KALV)

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 4:01 PM
Business Wire
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on the first day a closing price is reported following the grant date.


One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.


The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).


About KalVista Pharmaceuticals, Inc.

KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260402497914/en/
Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com
Molly Cameron

Senior Director, Corporate Affairs

(857) 356-0164

molly.cameron@kalvista.com


Original: KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista posts $49.1 million in EKTERLY revenue during eight-month transition periodMarch 25, 2026 8:39 AM
IH Market News
KalVista Pharmaceuticals Inc. (NASDAQ:KALV) reported global net product revenue of $49.1 million from its therapy EKTERLY during the eight-month period ending December 31, 2025, according to financial results covering the company’s fiscal transition period.Since launch through February, KalVista received 1,702 patient start forms in the United States, representing roughly 20% of the estimated U.S. patient population. During the same period, EKTERLY was prescribed by 724 unique clinicians. The company said most of its fourth-quarter 2025 revenue came from refill prescriptions for the hereditary angioedema treatment.EKTERLY was also introduced in Japan through KalVista’s partner Kaken Pharmaceutical Co., Ltd. and has been added to the country’s National Health Insurance reimbursement list. The oral, on-demand therapy is the first of its type to become available in the Japanese market.KalVista also completed enrollment for its Phase 3 KONFIDENT-KID trial evaluating sebetralstat in pediatric patients with hereditary angioedema aged 2 to 11, finishing recruitment a full year ahead of schedule. The company expects to submit a U.S. new drug application in the third quarter of 2026, with a potential launch targeted for 2027.For the eight-month transition period, the company reported cost of revenue of $3.1 million. Research and development expenses declined to $33.4 million from $52.2 million in the comparable period the previous year. Selling, general and administrative costs increased to $124.7 million from $64.9 million, largely reflecting commercialization spending tied to the EKTERLY launch.KalVista posted a net loss of $109.5 million, or $2.03 per share, compared with a net loss of $110.5 million, or $2.30 per share, in the prior year period. As of December 31, 2025, the company held approximately $300.2 million in cash, cash equivalents and marketable securities.KalVista recently shifted its fiscal year-end from April 30 to December 31, resulting in an eight-month reporting period spanning May 1, 2025 through December 31, 2025.KalVista Pharmaceuticals stock price

Original: KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership ConferenceMarch 20, 2026 7:00 AM
Business Wire
New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation


KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that five abstracts, including one late-breaking submission, have been accepted for presentation at the 2026 Global Angioedema Leadership Conference taking place in Madrid, Spain from March 26–29, 2026.


The following late-breaking abstract will be presented during the poster session on Friday, March 27 and as an oral presentation on Saturday, March 28 at 11:50 am CET:



On-demand Oral Sebetralstat for Hereditary Angioedema Attacks in Children Aged 2-11: Interim Analysis of KONFIDENT-KID: Emel Aygören-Pürsün, Adil Adatia, John Anderson, Shira Benor, Mélisande Bourgoin-Heck, Mauro Cancian, Bob Geng, Eisuke Inage, Aharon Kessel, Majed Koleilat, H. Henry Li, Michael E. Manning, Heloise Reumaux, Raffi Tachdjian, Paola Triggianese, Andrea Zanichelli, Erik Hansen, Ya-Hsiu Chuang, Matthew Iverson, Michael D. Smith, Paul K. Audhya, H. James Wedner.



The following poster presentations will take place during the poster session on Friday, March 27, beginning at 6:10 pm CET:



Satisfaction with Sebetralstat for HAE Attacks in Patients Switching from Parenteral On-demand Treatments in KONFIDENT-S: Mauro Cancian, Laurence Bouillet, Teresa Caballero, Tariq El-Shanawany, Sorena Kiani-Alikhan, Markus Magerl, Michael E. Manning, Inmaculada Martinez-Saguer, Maeve E. O’Connor, Sinisa Savic, Daniel F. Soteres, Maria Staevska, James Hao, Paolo Bajcic, Paul Audhya, Raffi Tachdjian.



On-demand Treatment Patterns of Hereditary Angioedema Attacks with Sebetralstat in the KONFIDENT-S Study: Mar Guilarte, Emel Aygören-Pürsün, Jonathan A. Bernstein, Danny M. Cohn, Vesna Grivcheva-Panovska, Tamar Kinaciyan, Damia Leguevaques, William R. Lumry, Michael E. Manning, Daniel F. Soteres, Petra Staubach, Raffi Tachdjian, Marcin Stobiecki, Marc A. Riedl, Anna Valerieva, Patrick F. K. Yong, Andrea Zanichelli, James Hao, Michael D. Smith, Paul K. Audhya, Henriette Farkas.



Barriers to Treatment of Hereditary Angioedema Attacks Among Patients Using Subcutaneous On-Demand Therapies: Insights from an International Patient Survey: Thomas Buttgereit, Isabelle Boccon-Gibod, Alexis Bocquet, Laurence Bouillet, Paula Busse, Sandra Christiansen, Timothy Craig, Tariq El-Shanawany, Tomaz Garcez, Padmalal Gurugama, Rashmi Jain, Sorena Kiani-Alikhan, Markus Magerl, Inmaculada Martinez-Saguer, Maeve O’Connor, Cristine Radojicic, Sinisa Savic, Paola Triggianese, H. James Wedner, Patrick Yong, Andrea Zanichelli, Sherry Danese, Julie Ulloa, Paolo Bajcic, Paul K. Audhya, Mauro Cancian.



Anxiety in Patients Using Injectable On-Demand Treatments for Hereditary Angioedema Attacks: Results from an International Patient Survey: Alexis Bocquet, Isabelle Boccon-Gibod, Laurence Bouillet, Paula Busse, Thomas Buttgereit, Sandra Christiansen, Timothy Craig, Tariq El-Shanawany, Tomaz Garcez, Padmalal Gurugama, Rashmi Jain, Sorena Kiani-Alikhan, Markus Magerl, Inmaculada Martinez-Saguer, Maeve O’Connor, Cristine Radojicic, Sinisa Savic, Paola Triggianese, H. James Wedner, Patrick Yong, Andrea Zanichelli, Sherry Danese, Julie Ulloa, Paolo Bajcic, Paul K. Audhya, Mauro Cancian.



Links to all presentations will be available on the KalVista website under Publications.


About Hereditary Angioedema

Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Treatment guidelines recommend treating attacks as early as possible to prevent progression of swelling and shorten the time to attack resolution, and to consider treatment for all attacks, regardless of anatomic location or severity.


About EKTERLY® (sebetralstat)

EKTERLY (sebetralstat) is a novel plasma kallikrein inhibitor approved in the United States, European Union, United Kingdom, Switzerland, Australia, Singapore and Japan for the treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. EKTERLY is the first and only oral on-demand treatment for HAE, offering efficacious and safe treatment of attacks without the burden of injections. With a US regulatory filing planned for 2026 to expand use to children aged 2–11, and additional filings anticipated in key global markets, EKTERLY has the potential to become the foundational therapy for HAE management worldwide. For more information, including the full US Prescribing Information, visit EKTERLY.com.


About KalVista Pharmaceuticals, Inc.

KalVista is a global pharmaceutical company dedicated to delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The KalVista team discovered and developed EKTERLY®—the first and only oral on-demand treatment for hereditary angioedema (HAE)—and continues to work closely with the global HAE community to improve treatment and care for this disease around the world. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.


Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "position," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, information relating to our business and business plans, the success of our efforts to commercialize EKTERLY® (sebetralstat), our ability to successfully obtain foreign regulatory approvals for sebetralstat, our expectations about the safety and efficacy of sebetralstat, the timing of clinical trials and their results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and the ability of EKTERLY to treat HAE. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2025, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260320091603/en/
Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com
Molly Cameron

Senior Director, Corporate Affairs

(978) 339-3378

molly.cameron@kalvista.com


Original: KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference

Looks like it wants to eclipse the 52 week high. Lots of insiders loading up over the past month.

KALV under $13

KALV 10Q expected July 5

KALV over $10

KALV new 52=week high

INSIDER PURCHASE / SYNDICATE

KALV - 10% OWNER Venrock Healthcare P 86,048 $14.618

KALV new 52 week high

KALV new 52 week high

I would not even buy the shares at $20.

All in puts!

Boom!

Killed it with puts today!

* * $KALV Video Chart 02-09-2021 * *

Link to Video - click here to watch the technical chart video

This company is a disaster...

The company is delinquent.

? lol

Profitability
Profit Margin 0.00%
Gross Profit (ttm) $-27.5M
EBITDA $-48.38M
Net Income Avi to Common (ttm) $-37.12M
Diluted EPS (ttm) -2.08

Book Value Per Share (mrq) $3.63

Going to keep diluting more and more

They are hemorrhaging money. Have pretty much zero revenue. They still have hundreds of millions to spend of your money until phase 3 and beyond.

Operating Margin (ttm) -905.50%

Management Effectiveness

Return on Assets (ttm) -32.60%
Return on Equity (ttm) -45.61%

Revenue  $5.4M
Revenue Per Share  $0.30

$KALV Kalvista Pharma Trend Break



Major Downtrend broken
Broken above 200ma
Volume increased
MACD reversed
RSi in bullish uptrend

News: $KALV KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr...

Find out more https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-appoints-daniel-b-soland-to-board-of-directors-8035190.html

News: $KALV KalVista Pharmaceuticals to Present at Needham Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, a...

Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-to-present-at-needham-healthcare-conference-7939130.html

KALV buy 28.87



normal chart







log chart

News: $KALV KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosi...

Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-7846828.html

Where is everyone?

$17.85 !!


KALV

Sniffer rocket ship today!! Wheeee.

KALV

$15.50 now ~ keep rollin



$KALV

http://m.nasdaq.com/article/sv-life-sciences-advisers-llc-buys-kalvista-pharmaceuticals-sells-raptor-pharmaceutical-cm744623

$8.25 now ~ keep rollin

any positive news and volume will move this north

LIVE action starting !!!

watching close ~

The way this is dropping, there has to be a lawsuit over the sale of cash at 60% off.
Where are those ambulance chasing securities lawyers?

So when will CBYL holders be issued KALV common stock?

CBYL is now KALV with a 1:14 reverse stock split.

Be very careful for the next few days as until all or most of the CBYL shares are converted to KALV, the only sellers will be private Kal Vista investors, those who bought after the symbol change and professionals. The price is likely to be high until existing CBYL retail holders can sell their shares. In addition, the existing CBYL shares will only represent 20% of the O/S. 80% will be held by the private investors in KVAL.

$6.00

New Ticker symbol now: KALV

Correction : $5.49 PM

WOW - look at this $0,89---> $4,60

New Ticker name now : KALV

look at NASDAQ - PM

Apparently the merger deal was approved by a huge margin.

Still don't get it.

* * $CBYL Video Chart 11-21-16 * *

Link to Video - click here to watch the technical chart video

Attempting to break 0.72. GL to holders

We'll see how this goes. Hopefully back to over a dollar.

CBYL continuing its upward momentum pre-market.

* * $CBYL Video Chart 11-18-16 * *

Link to Video - click here to watch the technical chart video

Oh okay. Im still up for it even if it is a merger. Good thing volume picked up today.

New buyer? They're not being bought, they're merging with another company and selling their cash at a steep discount.

Maybe the large shareholders decided it's better to take a smaller loss now by liquidating, than wait for a larger loss later and they're voting against the deal.

I can only hope!

Somethings fishy going on here. Why the sudden spike in volume? New buyer in sight?

Fun while it lasted.